StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly COVID-19 Antibodies by Quarter

COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy] ($M)

QuarterlyAnnual

Eli Lilly COVID-19 Antibodies: $0M in Q4 2023, down 100.0% from a year earlier. That is the lowest of the 16 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
0
Period ended Dec 31, 2023
Change on a year earlier
-100.0%
38 in Q4 2022
History
16 quarters
Since Q1 2020
Sources
12
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2025-02-19) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2023Dec 31, 20230-100.0%Form 10-K (filed 2025-02-19) ↗
Q3 2023Sep 30, 20230-100.0%Form 10-Q (filed 2023-11-02) ↗
Q2 2023Jun 30, 20230-100.0%Form 10-Q (filed 2023-08-08) ↗
Q1 2023Mar 31, 20230-100.0%Form 10-Q (filed 2023-04-27) ↗
Q4 2022Dec 31, 202238-96.3%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 2022387+79.4%Form 10-Q (filed 2023-11-02) ↗
Q2 2022Jun 30, 2022129+54.8%Form 10-Q (filed 2023-08-08) ↗
Q1 2022Mar 31, 20221,455+123.7%Form 10-Q (filed 2023-04-27) ↗
Q4 2021Dec 31, 20211,029+21.0%Form 10-K (filed 2024-02-21) ↗
Q3 2021Sep 30, 2021216–Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 202183.4–Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 2021651–Form 10-Q (filed 2022-04-29) ↗
Q4 2020Dec 31, 2020850–Form 10-K (filed 2023-02-22) ↗
Q3 2020Sep 30, 20200–Form 10-Q (filed 2021-10-27) ↗
Q2 2020Jun 30, 20200–Form 10-Q (filed 2021-08-03) ↗
Q1 2020Mar 31, 20200–Form 10-Q (filed 2021-04-30) ↗

Cite this data

StockData. (2026). Eli Lilly COVID-19 Antibodies ($M), quarterly Q1 2020–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-covid19antibodies-us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.